GSK Makes I-O Move With Merck KGaA Deal Worth Up To €3.7bn
Executive Summary
Already working with Pfizer on the immunotherapy Bavencio, Merck KGaA has bagged another big pharma player in GSK to progress what has been heralded by analysts as the German group's oncology game changer, M7824, which combines two powerful and synergistic anticancer mechanisms into one molecule.
You may also be interested in...
Merck KGaA Rebounds After COVID-19 Lockdowns
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
GSK Keeps Oncology 2.0 Growth Plans On Track
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
GSK Cancer R&D Chief Sees Three Key Approvals In Q2
GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.